Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Meneely who wrote (1345)	2/21/2000 4:18:00 PM
From: Larry Meneely	Read Replies (2) of 2344

Looking back at Biomira's 1998 news release for the phase I lung cancer study, I came across this tidbit: "In pre-clinical studies, BLP25 prevented the appearance of lung metastases when given in advance of a cancer cell line expressing human MUC-1. In other BLP25 experiments, where the vaccine was given after cancer nodules had already developed in the lung, the cancer cells were almost entirely eradicated." biomira.com The indication was there from the start that this product is different. PS Regarding institutional investing, I have noticed a much increased (US)institutional investment activity per Thomson I-Watch. You can follow it daily here: thomsoninvest.net Larry Meneely

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next